Total Hip Arthroplasty
Conditions
Brief summary
To observe the clinical effect of esketamine combined with hip capsule peripheral nerve block in elderly patients undergoing total hip arthroplasty. A total of 120 elderly patients who underwent total hip arthroplasty in our hospital from January 2020 to May 2021 were randomly divided into three groups, 40 cases in each group. The observation group A was treated with esketamine subanesthetic dose combined with hip capsule peripheral nerve block, the control group B was treated with esketamine subanesthetic dose combined with lumbar plexus block, and the control group C was treated with esketamine subanesthetic dose for general anesthesia. The onset time of anesthesia, duration of block, postoperative recovery time, postoperative extubation time, MAP and HR indexes before anesthesia (T0), during skin incision (T1), 30 minutes after the start of surgery (T2), and at the end of surgery (T3) were recorded in the three groups, and the VAS score and Ramsay score at 0.5 h, 2 h, 6 h, 12 h, and 24 h after surgery, as well as the incidence of postoperative adverse reactions were recorded in the three groups.
Interventions
DRUGesketamine sub-anesthetic,
the use of esketamine sub-anesthetic dose combined with hip capsule peripheral nerve block
DRUGesketamine sub-anesthetic
Esketamine subanesthetic dose combined with lumbar plexus block was used
Sponsors
Changzhou Traditional Chinese Medicine Hospital Affiliated to Nanjing University of Chinese Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients aged ≥ 60 years * American Society of Anesthesiology (ASA) II or III * No serious coronary heart disease, hypertension, diabetes and related complications, no serious liver and kidney function damage, no mental illness
Exclusion criteria
* Allergic to ketamine * Abnormal coagulation function * Mental system diseases or cognitive dysfunction * Severe liver and kidney dysfunction
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Anesthesia indicators | onset time of anesthesia 5 minutes | Add a onset time of anesthesia Outcome Measure |
| Vital signs | before anesthesia (T0) | mean arterial pressure before anesthesia (T0) |
| Visual Analogue Scale | 0.5hour | Visual Analogue Scale score (0 is no pain; 0 \ 4 is mild pain; 4 \ 7 is moderate pain; 7 \ 10 is severe pain) |
| Ramsay sedation score | 0.5hour | Ramsay score (range 0\ 6 points, 1 point for insufficient sedation, 2\ 4 points for good sedation, 5\ 6 points for excessive sedation) |
| Adverse reactions | at the end of surgery 48 hours | the incidence of postoperative delirium, nausea and vomiting, drowsiness, skin itching and other adverse reactions |
Countries
China
Outcome results
None listed